Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
News|Podcasts|November 16, 2026

ACT Brief: Screening Inconsistencies in Oncology, FDA Voucher Pilot Pause, and Patient AI Use

In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

  • In part two of a video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, describes how physician awareness and site-level access drive screening inconsistencies. He explains why acceptance rates are the same across backgrounds once patients are simply asked.
  • The FDA has reportedly paused its Commissioner’s National Priority Voucher pilot, according to a Reuters report that Fierce Pharma cited, and the agency is still accepting applications but not reviewing or granting new ones. HHS says work under the program is ongoing, and 22 drug programs have received the voucher, with 12 approvals and one rejection. The program, which shortens review from the regular 10 months to one to two months, has drawn concerns about political favoritism and lack of transparency.
  • In an interview with Pharmaceutical Executive, Stacy Hurt of Parexel says about 60% of Americans now use AI-related tools such as ChatGPT for their own health. She encourages patients to take their diagnosis and plan of care into these tools, then bring the results to their physician to build a collaborative treatment plan. The goal, she says, is to empower patients to have an informed dialogue with their healthcare team.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.


Related to this article

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.